Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 16;8(2):103.
doi: 10.3390/pharmacy8020103.

Ingestible Sensors and Medication Adherence: Focus on Use in Serious Mental Illness

Azita Alipour  1 , Stephen Gabrielson  2 , Puja Baldev Patel  1
Affiliations
Review

Ingestible Sensors and Medication Adherence: Focus on Use in Serious Mental Illness

Azita Alipour et al. Pharmacy (Basel). .

Abstract

Background: Poor medication adherence is a major public health concern. Patients living with a serious mental illness (SMI) commonly present with non-adherence to their medication regimen, which can lead to relapse and hospitalizations. The high rates of antipsychotic non-adherence continue to persist despite several interventions and medication advances. This review evaluates the possible role of the ingestible sensor technology for medication adherence in different conditions, with a focus on use in the SMI schizophrenia.

Methods: Literature searches were conducted in July 2019 in the PubMed database.

Results: In small studies of ingestible sensor use, the average adherence ranged from 73.9% to 88.6% for SMI and ≥ 80% for cardiac and transplant (99.4%) patients. In SMI studies, patients were clinically stable, and the majority had a clinical global impression severity of "mild disease". Patients generally experienced relatively minor dermatological adverse effects related to wearable sensor use.

Conclusions: A medication with an ingestible sensor may help provide real-time objective medication-taking adherence information for clinicians. However, further studies are needed to understand the impact of use on adherence and improvement on treatment outcomes with the ingestible sensor technology.

Keywords: adherence; antipsychotic; ingestible sensor; schizophrenia; serious mental illness.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. World Health Organization . Asthma. In: World Health Organization, editor. Adherence to Long-Term Therapies: Evidence for Action. World Health Organization; Geneva, Switzerland: 2003. pp. 47–58.
    1. Sendt K.V., Tracy D.K., Bhattacharyya S. A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders. Psychiatry Res. 2015;225:14–30. doi: 10.1016/j.psychres.2014.11.002. - DOI - PubMed
    1. Baumgartner P.C., Haynes R.B., Hersberger K.E., Arnet I. A Systematic Review of Medication Adherence Thresholds Dependent of Clinical Outcomes. Front. Pharmacol. 2018;9:1–10. doi: 10.3389/fphar.2018.01290. - DOI - PMC - PubMed
    1. Stentzel U., van den Berg N., Schulze L.N., Schwaneberg T., Radicke F., Langosch J.M., Freyberger H.J., Hoffmann W., Grabe H.J. Predictors of medication adherence among patients with severe psychiatric disorders: Findings from the baseline assessment of a randomized controlled trial (Tecla) BMC Psychiatry. 2018;18:1–8. doi: 10.1186/s12888-018-1737-4. - DOI - PMC - PubMed
    1. Schulze L.N., Stentzel U., Leipert J., Schulte J., Langosch J., Freyberger H.J., Hoffmann W., Grabe H.J., van den Berg N. Improving Medication Adherence With Telemedicine for Adults With Severe Mental Illness. Psychiatr. Serv. (Wash. D.C.) 2019;70:225–228. doi: 10.1176/appi.ps.201800286. - DOI - PubMed

LinkOut - more resources